Contact
Please use this form to send email to PR contact of this press release:
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of TALTZ® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
TO: